Alexion Pharmaceutical Inc. diskutieren
Alexion Pharmaceutical Inc.
WKN: 899527 / Symbol: ALXN / Name: Alexion / Aktie / Pharmazeutika / Large Cap /
154,78 €
1,26 %
Alexion wird von J.P. Morgan Analyst Cory Kasimov mit Kursziel 167 USD empfohlen
https://www.nasdaq.com/articles/j.p.-morgan%3A-these-2-healthcare-stocks-are-must-watch-names-2020-08-05
Auf TipRanks
https://www.tipranks.com/analysts/cory-kasimov
https://www.nasdaq.com/articles/j.p.-morgan%3A-these-2-healthcare-stocks-are-must-watch-names-2020-08-05
Auf TipRanks
https://www.tipranks.com/analysts/cory-kasimov
Alexion wird gleich in 2 Artikeln 3 stocks to buy mit einer positiven Einschätzung versehen
https://www.nasdaq.com/articles/3-stocks-to-buy-when-the-stock-market-crashes-2020-08-11
As a reminder, economic conditions are unlikely to ever phase Alexion. Since it provides unique therapies, it has little issue garnering insurer coverage for its treatments. Likewise, patients usually need ongoing care, which means a recession should have virtually no impact on demand for Alexion's drugs. This is the type of stock you can buy with confidence if and when the stock market plunges.
https://www.nasdaq.com/articles/3-stocks-to-buy-when-the-stock-market-crashes-2020-08-11
As a reminder, economic conditions are unlikely to ever phase Alexion. Since it provides unique therapies, it has little issue garnering insurer coverage for its treatments. Likewise, patients usually need ongoing care, which means a recession should have virtually no impact on demand for Alexion's drugs. This is the type of stock you can buy with confidence if and when the stock market plunges.
https://www.nasdaq.com/articles/3-stocks-to-buy-if-you-think-trump-will-win-the-election-2020-08-12
Even though President Trump signed a number of executive orders on drug pricing just a few weeks ago that would allow for the importation of certain drugs from Canada and require pharmacy-benefit managers to alter how they pass along discounts to Medicare patients, the consensus is that these orders have no teeth. They're either going to take a while to implement or won't be adhered to at all.
In other words, brand-name drug-pricing power should remain hearty for the foreseeable future. That's good news for Alexion, which has developed some of the most expensive therapies in the world. In all fairness, Alexion targets a handful of ultra-rare indications with its therapies, so it's merely trying to recoup its development costs, as well as the expenses tied to failed clinical trials.
Even though President Trump signed a number of executive orders on drug pricing just a few weeks ago that would allow for the importation of certain drugs from Canada and require pharmacy-benefit managers to alter how they pass along discounts to Medicare patients, the consensus is that these orders have no teeth. They're either going to take a while to implement or won't be adhered to at all.
In other words, brand-name drug-pricing power should remain hearty for the foreseeable future. That's good news for Alexion, which has developed some of the most expensive therapies in the world. In all fairness, Alexion targets a handful of ultra-rare indications with its therapies, so it's merely trying to recoup its development costs, as well as the expenses tied to failed clinical trials.
Sell Alexion Pharmaceutical Inc.
Sell Alexion Pharmaceutical Inc.
Alexion heute an der NASDAQ mit 8% im Plus ohne erkennbaren Newsflow
ValueFreak schrieb am 31.08.20:
Alexion heute an der NASDAQ mit 8% im Plus ohne erkennbaren Newsflow
Die EU-Kommission hat Alexion die Erweiterung der bisherigen Zulassung für Soliris (Eculizumab) erteilt: Der monoklonale Antikörper ist ab sofort auch zur Behandlung von Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)* bei erwachsenen Patienten, die positiv für Aquaporin-4(AQP4)-Antikörper sind und einen schubförmigen Krankheitsverlauf zeigen, zugelassen. Damit stellt er die erste und einzige Behandlungsoption dar.
* NMOSD sind seltene und schwerwiegende entzündliche Autoimmunerkrankungen des zentralen Nervensystems (ZNS).
klostergang schrieb am 31.08.20:
ValueFreak schrieb am 31.08.20:Alexion heute an der NASDAQ mit 8% im Plus ohne erkennbaren Newsflow
Die EU-Kommission hat Alexion die Erweiterung der bisherigen Zulassung für Soliris (Eculizumab) erteilt: Der monoklonale Antikörper ist ab sofort auch zur Behandlung von Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)* bei erwachsenen Patienten, die positiv für Aquaporin-4(AQP4)-Antikörper sind und einen schubförmigen Krankheitsverlauf zeigen, zugelassen. Damit stellt er die erste und einzige Behandlungsoption dar.
* NMOSD sind seltene und schwerwiegende entzündliche Autoimmunerkrankungen des zentralen Nervensystems (ZNS).
Da muss man wohl Apotheker sein, um diese Meldung zu finden
https://www.apotheke-adhoc.de/nachrichten/detail/pharmazie/soliris-erhaelt-zulassungserweiterung-erste-behandlungsoption-fuer-nmosd/
Virtual Investor Day bei Alexion
https://ir.alexion.com/news-releases/news-release-details/alexion-highlights-promising-pipeline-distinguished-rare-disease
Mehr als 100 schwer verdauliche Seiten Präsentation - ich beneide nicht die Teilnehmer
https://ir.alexion.com/static-files/ebdf1262-b96e-4d3b-a4e8-0d0c04ebae77
Aber es gibt ein paar leicht verständliche Highlights
https://ir.alexion.com/news-releases/news-release-details/alexion-highlights-promising-pipeline-distinguished-rare-disease
Mehr als 100 schwer verdauliche Seiten Präsentation - ich beneide nicht die Teilnehmer
https://ir.alexion.com/static-files/ebdf1262-b96e-4d3b-a4e8-0d0c04ebae77
Aber es gibt ein paar leicht verständliche Highlights
- Robust pipeline of 20+ development programs across 7 rare disease franchises with future plans to continue growing pipeline with >5 novel INDs by 2025
- Increasing depth and breadth of growth opportunities expected to generate 2025 global revenues of $9-10 billion & >10% revenue CAGR through 2025 and beyond
- Expect to raise 2020 full-year revenue guidance by >$200 million
- Robust share repurchase commitment expected to return ~$3 billion cash to shareholders through 2023
Das sieht mir nach Kursgewinnen in der nahen Zukunft aus.
Alexion mit guten Quartalsergebnissen
https://ir.alexion.com/news-releases/news-release-details/alexion-reports-third-quarter-2020-results
https://ir.alexion.com/news-releases/news-release-details/alexion-reports-third-quarter-2020-results
- 3Q20 total revenues of $1,588.7 million, a 26% increase over 3Q19
- GAAP diluted EPS was $2.62, compared to $2.08 in the third quarter of 2019
- Non-GAAP diluted EPS was $3.24, compared to $2.79 in the third quarter of 2019.
- Received Japanese approval for ULTOMIRIS® (ravulizumab) in atypical hemolytic uremic syndrome (aHUS)
- Received U.S. approval & positive CHMP opinion for ULTOMIRIS 100 mg/mL higher concentration formulation in paroxysmal nocturnal hemoglobinuria (PNH) & aHUS
- Established ULTOMIRIS as new standard of care in PNH ahead of set goal, with more than 70% patient conversion from SOLIRIS® (eculizumab) in 3 largest markets - U.S., Germany & Japan
- Initiated Phase 3 program for CAEL-101 in AL amyloidosis in collaboration with Caelum Biosciences
- Raised full year guidance, driven by increased revenue guidance of $350 million
AstraZeneca will Alexion übernehmen
https://www.wsj.com/articles/astrazeneca-agrees-to-buy-alexion-for-39-billion-11607778687
https://www.wsj.com/articles/astrazeneca-agrees-to-buy-alexion-for-39-billion-11607778687
AstraZeneca said its cash-and-stock agreement amounts to $175 per Alexion share, based on the one-month average value of AstraZeneca’s U.S.-traded American depositary receipts. The offer is split between $60 in cash and 2.1243 American depositary shares. That represents a 40% premium over Alexion’s one-month share-price average, AstraZeneca said. Alexion’s shares closed Friday at $120.98.
Buy mit Kursziel 140,0
Buy Alexion Pharmaceutical Inc.
Zweifel an der Fairness des AstraZeneca Angebotes
https://finance.yahoo.com/news/alexion-merger-investigation-halper-sadeh-140700893.html
Mir kommt der Preis, den AstraZeneca zahlen will, auch zu niedrig vor angesichts der Wachstumsdynamik von Alexion.
https://finance.yahoo.com/news/alexion-merger-investigation-halper-sadeh-140700893.html
Mir kommt der Preis, den AstraZeneca zahlen will, auch zu niedrig vor angesichts der Wachstumsdynamik von Alexion.
Kursziel geändert auf 132,0
Einschätzung beendet - ich sehe jetzt größeres Potential bei AstraZeneca.
Kursziel geändert auf 200,0
Buy Alexion Pharmaceutical Inc.
Kursziel geändert auf 0,0
Kursziel geändert auf 145,0
Buy Alexion Pharmaceutical Inc.
Neueste Beiträge
Subdi in Tesla Inc diskutieren